Safety of Sirolimus in Patients with Tuberous Sclerosis Complex under Two Years of Age—A Bicenter Retrospective Study

Background: mTOR inhibitors are a novel pharmacotherapy recommended for subependymal giant astrocytomas, refractory epilepsy, and the treatment of the other clinical manifestations of tuberous sclerosis complex (TSC). Clinical trials on everolimus proved it to be effective and safe in children. Desp...

Descripción completa

Detalles Bibliográficos
Autores principales: Śmiałek, Dominika, Jóźwiak, Sergiusz, Kotulska, Katarzyna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9821318/
https://www.ncbi.nlm.nih.gov/pubmed/36615165
http://dx.doi.org/10.3390/jcm12010365

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9821318/
https://www.ncbi.nlm.nih.gov/pubmed/36615165
http://dx.doi.org/10.3390/jcm12010365

Ejemplares similares